{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sarcomatoid+Carcinoma",
    "query": {
      "condition": "Sarcomatoid Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sarcomatoid+Carcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:43:21.800Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03912818",
      "title": "Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Adenocarcinoma",
        "Bladder Mixed Adenocarcinoma",
        "Bladder Squamous Cell Carcinoma",
        "Bladder Urothelial Carcinoma",
        "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant",
        "Infiltrating Bladder Urothelial Carcinoma With Giant Cells",
        "Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation",
        "Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation",
        "Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Nested Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cystectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2019-04-10",
      "completion_date": "2022-08-11",
      "has_results": true,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03912818"
    },
    {
      "nct_id": "NCT06049576",
      "title": "Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Myrciaria dubia Prebiotic Supplement",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2023-10-06",
      "completion_date": "2026-06-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06049576"
    },
    {
      "nct_id": "NCT06866262",
      "title": "Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Clear Cell Renal Cell Carcinoma",
        "Locally Advanced Sarcomatoid Renal Cell Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Metastatic Sarcomatoid Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Inulin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DIETARY_SUPPLEMENT",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2025-08-15",
      "completion_date": "2031-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06866262"
    },
    {
      "nct_id": "NCT03055013",
      "title": "Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage II Renal Cell Cancer AJCC v7",
        "Stage III Renal Cell Cancer AJCC v7",
        "Unclassified Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nephrectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 819,
      "start_date": "2017-04-28",
      "completion_date": "2031-06-09",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 396,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 293 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03055013"
    },
    {
      "nct_id": "NCT07128680",
      "title": "Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Cell Carcinoma",
        "Advanced Sarcomatoid Renal Cell Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Metastatic Sarcomatoid Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DIETARY_SUPPLEMENT",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2026-03-23",
      "completion_date": "2028-08-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Irvine, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07128680"
    },
    {
      "nct_id": "NCT02029690",
      "title": "Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pleural Mesothelioma Malignant Advanced",
        "Peritoneal Mesothelioma Malignant Advanced",
        "Non-squamous Non-small Cell Lung Carcinoma",
        "Uveal Melanoma",
        "Hepatocellular Carcinoma",
        "Glioma",
        "Sarcomatoid Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Polaris Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2014-04-23",
      "completion_date": "2020-06",
      "has_results": false,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02029690"
    },
    {
      "nct_id": "NCT03541902",
      "title": "Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplasms of Urinary Tract",
        "Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Papillary Renal Cell Carcinoma",
        "Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Unclassified Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2018-05-15",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 3,
      "location_summary": "Houston, Texas • Sugar Land, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03541902"
    },
    {
      "nct_id": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acinar Cell Carcinoma",
        "Adenoid Cystic Carcinoma",
        "Adrenal Cortical Carcinoma",
        "Adrenal Gland Pheochromocytoma",
        "Anal Canal Neuroendocrine Carcinoma",
        "Anal Canal Undifferentiated Carcinoma",
        "Angiosarcoma",
        "Apocrine Neoplasm",
        "Appendix Mucinous Adenocarcinoma",
        "Bartholin Gland Transitional Cell Carcinoma",
        "Basal Cell Carcinoma",
        "Bladder Adenocarcinoma",
        "Breast Metaplastic Carcinoma",
        "Cervical Adenocarcinoma",
        "Cholangiocarcinoma",
        "Chordoma",
        "Colorectal Squamous Cell Carcinoma",
        "Desmoid Fibromatosis",
        "Endometrial Transitional Cell Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Esophageal Neuroendocrine Carcinoma",
        "Esophageal Undifferentiated Carcinoma",
        "Extrahepatic Bile Duct Carcinoma",
        "Extramammary Paget Disease",
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fibromyxoid Tumor",
        "Gallbladder Carcinoma",
        "Gastric Neuroendocrine Carcinoma",
        "Gastric Squamous Cell Carcinoma",
        "Gastric Undifferentiated Carcinoma",
        "Gastrointestinal Stromal Tumor",
        "Gestational Trophoblastic Tumor",
        "Giant Cell Carcinoma",
        "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type",
        "Intestinal Neuroendocrine Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Lung Neuroendocrine Tumor",
        "Lung Sarcomatoid Carcinoma",
        "Major Salivary Gland Carcinoma",
        "Malignant Neoplasm of Unknown Primary",
        "Malignant Odontogenic Neoplasm",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Malignant Solid Neoplasm",
        "Malignant Testicular Sex Cord-Stromal Tumor",
        "Metastatic Pituitary Neuroendocrine Tumor",
        "Minimally Invasive Lung Adenocarcinoma",
        "Mixed Mesodermal (Mullerian) Tumor",
        "Mucinous Adenocarcinoma",
        "Mucinous Cystadenocarcinoma",
        "Nasal Cavity Adenocarcinoma",
        "Nasal Cavity Carcinoma",
        "Nasopharyngeal Carcinoma",
        "Nasopharyngeal Low Grade Papillary Adenocarcinoma",
        "Nasopharyngeal Undifferentiated Carcinoma",
        "Oral Cavity Carcinoma",
        "Oropharyngeal Undifferentiated Carcinoma",
        "Ovarian Adenocarcinoma",
        "Ovarian Germ Cell Tumor",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Squamous Cell Carcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Pancreatic Acinar Cell Carcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Paraganglioma",
        "Paranasal Sinus Adenocarcinoma",
        "Paranasal Sinus Carcinoma",
        "Parathyroid Gland Carcinoma",
        "PEComa",
        "Penile Squamous Cell Carcinoma",
        "Peritoneal Mesothelial Neoplasm",
        "Placental Choriocarcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Pseudomyxoma Peritonei",
        "Rare Disorder",
        "Scrotal Squamous Cell Carcinoma",
        "Seminal Vesicle Adenocarcinoma",
        "Seminoma",
        "Serous Cystadenocarcinoma",
        "Small Intestinal Adenocarcinoma",
        "Small Intestinal Squamous Cell Carcinoma",
        "Spindle Cell Neoplasm",
        "Teratoma With Somatic-Type Malignancy",
        "Testicular Non-Seminomatous Germ Cell Tumor",
        "Thyroid Gland Carcinoma",
        "Tracheal Carcinoma",
        "Transitional Cell Carcinoma",
        "Ureter Adenocarcinoma",
        "Ureter Squamous Cell Carcinoma",
        "Urethral Adenocarcinoma",
        "Urethral Squamous Cell Carcinoma",
        "Vaginal Adenocarcinoma",
        "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "Vulvar Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 818,
      "start_date": "2017-01-30",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 1007,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834013"
    },
    {
      "nct_id": "NCT03483883",
      "title": "Avelumab/Gemcitabine in Sarcomatoid RCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic sRCC"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2018-03-19",
      "completion_date": "2021-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-08-26",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03483883"
    },
    {
      "nct_id": "NCT00035243",
      "title": "EPO906 Therapy in Patients With Advanced Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Neoplasms"
      ],
      "interventions": [
        {
          "name": "epothilone b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 53,
      "start_date": "2002-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-04-17",
      "last_synced_at": "2026-05-22T05:43:21.800Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035243"
    }
  ]
}